Skip to main content
. 2022 May 5;12:7326. doi: 10.1038/s41598-022-11033-x

Figure 2.

Figure 2

FGF21 induces hypertrophic growth of cultured cardiac myocytes in the presence of high glucose via FGFR4. (a) Transmitted light images of primary adult rat ventricular myocytes (ARVMs) treated with BSA (control), and mouse recombinant FGF21 (25 ng/ml) with or without 10 mM increased glucose (final 5.6 or 15.6 mM) for 48 h (scale bar = 25 µm), and (b–d) myocyte length, width, and width to length ratio. FGFR4-specific blocking antibody (anti-FGFR4; 10 mg/ml) was included as indicated. (e) Images of ARVMs treated with BSA (control), and FGF21 (25 ng/ml) with or without phenylephrine (PE; 20 µM) or isoproterenol (Iso; 10 µM) for 48 h (scale bar = 25 µm), and (f–h) myocyte length, width, and width to length ratio. Comparison between groups was performed in form of a one-way (b–d, f–h) ANOVA followed by post-hoc Tukey test. All values are expressed as mean ± SEM. (b–d) N = 5, ^p ≤ 0.05 vs. BSA Control, #p ≤ 0.05 vs. FGF21 Control, *p ≤ 0.05 vs. Glucose Control. (f–h) N = 4, *p ≤ 0.05 vs. respective Control.